You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 297 No. 2, January 10, 2007 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (2)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Drug Therapy, Other
 •Prognosis/ Outcomes
 •Cardiovascular Disease/ Myocardial Infarction
 •Alert me on articles by topic

Does Clopidogrel Each Day Keep Stent Thrombosis Away?

Dean J. Kereiakes, MD

JAMA. 2007;297:209-211.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

New medicines and new methods of cure always work miracles . . . for a while.
William Heberden, MD

The polymer-based elution of antiproliferative medications from a metal stent prosthesis has been demonstrated to suppress neointimal proliferative response to stent-vessel injury and to reduce consequent late arterial lumen loss and restenosis. In randomized controlled trials, drug-eluting stents compared with bare-metal stents caused a 70% to 80% reduction in binary (>50%) angiographic restenosis and a 50% to 70% reduction in repeat target lesion or vessel revascularization.1-2 Furthermore, comprehensive follow-up to 1 year demonstrated no evidence for any excess in the incidence of death, myocardial infarction (MI), or stent thrombosis for either treatment strategy.3-4 Thus, based on pivotal clinical trial evidence for both the relative safety and efficacy of drug-eluting stents, the US Food and Drug Administration approved both Cypher, the sirolimus-eluting stent, in 2002, as well as TAXUS, the paclitaxel-eluting . . . [Full Text of this Article]

Author Affiliations: The Heart Center of Greater Cincinnati and The Lindner Research Center at The Christ Hospital, Cincinnati, Ohio; and The Ohio State University, Columbus.


RELATED ARTICLE

Clopidogrel Use and Long-term Clinical Outcomes After Drug-Eluting Stent Implantation
Eric L. Eisenstein, Kevin J. Anstrom, David F. Kong, Linda K. Shaw, Robert H. Tuttle, Daniel B. Mark, Judith M. Kramer, Robert A. Harrington, David B. Matchar, David E. Kandzari, Eric D. Peterson, Kevin A. Schulman, and Robert M. Califf
JAMA. 2007;297(2):159-168.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Thrombosis and Drug-Eluting Stents: An Objective Appraisal
Holmes et al.
J Am Coll Cardiol 2007;50:109-118.
ABSTRACT | FULL TEXT  

Patients with drug eluting stents do better on long term clopidogrel
BMJ 2007;334:119-119.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.